

Carl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2874660/publications.pdf>

Version: 2024-02-01

31
papers

5,712
citations

567144
15
h-index

501076
28
g-index

31
all docs

31
docs citations

31
times ranked

7707
citing authors

#	ARTICLE	IF	CITATIONS
1	The year in cardiovascular medicine 2021: dyslipidaemia. European Heart Journal, 2022, , .	1.0	9
2	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in Cardiovascular Diseases, 2022, 73, 32-40.	1.6	19
3	LDL-C Estimation. Journal of the American College of Cardiology, 2022, 79, 542-544.	1.2	5
4	Managing Atherosclerotic Cardiovascular Risk in Young Adults. Journal of the American College of Cardiology, 2022, 79, 819-836.	1.2	72
5	The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. Journal of Clinical Lipidology, 2021, 15, 33-60.	0.6	105
6	How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. European Heart Journal, 2021, 42, 2154-2169.	1.0	28
7	In Replyâ€“Coronary Artery Calcium Scores I and II. Mayo Clinic Proceedings, 2021, 96, 262-263.	1.4	0
8	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clinic Proceedings, 2021, 96, 2660-2670.	1.4	7
9	Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. Journal of Clinical Lipidology, 2021, , .	0.6	2
10	Modeling the Recommended Age for Initiating Coronary Artery Calcium Testing Among At-Risk Young Adults. Journal of the American College of Cardiology, 2021, 78, 1573-1583.	1.2	31
11	PCSK9 inhibition for acute arterial events: more than LDL lowering. European Heart Journal, 2021, 42, 4830-4832.	1.0	2
12	How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines. Methodist DeBakey Cardiovascular Journal, 2021, 15, 16.	0.5	1
13	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. Trends in Cardiovascular Medicine, 2020, 30, 151-157.	2.3	3
14	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. Journal of the American Heart Association, 2020, 9, e018189.	1.6	4
15	When a â€œnormalâ€•cholesterol level is not normal: Exposing an unusual presentation of familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 414-418.	0.6	0
16	HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 Words. Mayo Clinic Proceedings, 2020, 95, 1740-1749.	1.4	10
17	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Journal of Clinical Lipidology, 2019, 13, 860-872.	0.6	79
18	JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product. Journal of Clinical Lipidology, 2019, 13, 345-355.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2019, 13, 374-392.	0.6	315
20	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2019, 13, 525-537.	0.6	45
21	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, e285-e350.	1.2	1,550
22	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1082-e1143.	1.6	2,380
23	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. Journal of Clinical Lipidology, 2017, 11, 880-890.	0.6	85
24	Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease prevention. Journal of Clinical Lipidology, 2016, 10, 458-461.	0.6	2
25	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2016, 68, 92-125.	1.2	371
26	Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surgery for Obesity and Related Diseases, 2016, 12, 468-495.	1.0	45
27	Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. Journal of Clinical Lipidology, 2016, 10, 905-914.	0.6	54
28	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. Journal of Clinical Lipidology, 2016, 10, 33-57.	0.6	39
29	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. Journal of Clinical Lipidology, 2016, 10, 15-32.	0.6	17
30	Clinical lipidology: A subspecialty whose time has come. Journal of Clinical Lipidology, 2015, 9, 634-639.	0.6	2
31	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology, 2015, 9, S1-S122.e1.	0.6	430